FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107370425> ?p ?o ?g. }

• W2107370425 endingPage "844" @default.
• W2107370425 startingPage "838" @default.
• W2107370425 abstract "No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Mar 2000AN IMPLANT RELEASING THE GONADOTROPIN HORMONE-RELEASING HORMONE AGONIST HISTRELIN MAINTAINS MEDICAL CASTRATION FOR UP TO 30 MONTHS IN METASTATIC PROSTATE CANCER BORIS CHERTIN, IRVING M. SPITZ, TZINA LINDENBERG, NURIT ALGUR, TAMI ZER, PETR KUZMA, ALFRED J. MOO YOUNG, RAPHAEL CATANE, and AMICUR FARKAS BORIS CHERTINBORIS CHERTIN More articles by this author , IRVING M. SPITZIRVING M. SPITZ More articles by this author , TZINA LINDENBERGTZINA LINDENBERG More articles by this author , NURIT ALGURNURIT ALGUR More articles by this author , TAMI ZERTAMI ZER More articles by this author , PETR KUZMAPETR KUZMA More articles by this author , ALFRED J. MOO YOUNGALFRED J. MOO YOUNG More articles by this author , RAPHAEL CATANERAPHAEL CATANE More articles by this author , and AMICUR FARKASAMICUR FARKAS More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)67816-0AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The administration of gonadotropin hormone-releasing hormone agonists is well established for treating metastatic prostate cancer. In an ongoing study we evaluated the effect of a long acting implant that releases the gonadotropin hormone-releasing hormone agonist histrelin ([ImBzl]D-His6, Pro9-Net) in 15 patients with disseminated prostate cancer. Materials and Methods: The 2.6 cm. implant releasing 60 μg. histrelin daily is inserted subcutaneously into the upper arm using local anesthesia. Of the patients 8 received 1 and the remainder received 2 implants. Treatment with the antiandrogen flutamide or cyproterone acetate began 2 weeks before implant insertion and continued for up to 12 weeks. Testosterone, luteinizing hormone (LH) and prostate specific antigen were determined monthly, and a metastatic evaluation was performed every 6 months. Results: LH and testosterone increased after flutamide administration and decreased after implant insertion. By day 28 LH and testosterone were completely suppressed. LH and testosterone decreased immediately after cyproterone acetate administration. Prostate specific antigen began to decrease during antiandrogen therapy and decreased further after implant insertion. One patient requested implant removal after 1 year for personal reasons and 1 died of an unrelated cause 18 months after insertion. Escape was demonstrated in 4 cases at 5, 10, 12 and 19 months, although LH and testosterone remained suppressed. Duration of treatment in the remaining 9 patients was between 21 and 30 months. LH and testosterone remained completely suppressed and prostate specific antigen levels were in the normal range. The clinical and biochemical response was identical in those who received 1 or 2 implants. At 12 months 8 patients were challenged at intermittent intervals for up to 24 months with a bolus of 100 μg. gonadotropin hormone-releasing hormone followed by 2 weeks of flutamide. The response was compared with that in untreated controls recently diagnosed with prostate cancer. Unlike controls there was complete LH suppression in the 8 challenged patients. Conclusions: A histrelin implant suppresses LH and testosterone in prostate cancer for up to 30 months. This finding represents a significant improvement over existing preparations, which must be administered at 1 to 3-month intervals. References 1 : Management of hormone refractory prostate cancer: current standards and future prospects. J Urol1998; 160: 1220. Link, Google Scholar 2 : Patients’ choice of treatment in stage D prostate cancer. Urology1989; 33: 57. Google Scholar 3 : Management of cancer of the prostate. N Engl J Med1994; 331: 996. Google Scholar 4 : A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med1989; 321: 419. Crossref, Medline, Google Scholar 5 : Current status of combined androgen blockade: optimal therapy for advanced prostate cancer. J Clin Endocrinol Metab1995; 80: 1062. Google Scholar 6 : A new long acting formulation of the luteinizing hormone-releasing hormone analogue goserelin: results of studies in prostate cancer. J Urol1996; 155: 1352. Link, Google Scholar 7 : A new extra long acting depot preparation of the LH-RH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer. J Steroid Biochem Mol Biol1990; 37: 933. Google Scholar 8 : Recent advances in the medical management of prostate cancer. Br J Clin Pract1996; 50: 88. Google Scholar 9 : Randomised controlled study of orchidectomy vs long acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet1985; 2: 1201. Google Scholar 10 : Orchidectomy or LHRH-analogue? Which do the patients prefer and what treatment would Norwegian urologists prefer if they had advanced cancer of the prostate?. Scand J Urol Nephrol1991; 25: 197. Google Scholar 11 : Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma. J Clin Endocrinol Metab1984; 58: 397. Google Scholar 12 : Progress in complete androgen blockade. Eur Urol1997; 31: 8. Google Scholar 13 : Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am1975; 2: 125. Google Scholar 14 : Gonadotropin-releasing hormone (GnRH), GnRH superagonists, and GnRH antagonists. In: . New York: Chapman and Hall1995: 887. chapt. 54. Google Scholar 15 : Gonadotropin-releasing hormone receptors: characterization, physiological regulation, and relationship to reproductive function. Endocr Rev1981; 2: 186. Google Scholar 16 : Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer. N Engl J Med1999; 340: 1439. Google Scholar 17 : Diagnosis and staging of prostate cancer. In: . Philadelphia: W. B. Saunders1998: 2519. chapt. 83. Google Scholar 18 : Hydron implant for continuous treatment of prostate cancer: twelve months and beyond. Presented at annual meeting of Biomaterials, Providence, Rhode IslandJune 1999; . Google Scholar 19 : The effect of flutamide on testosterone metabolism and the plasma levels of androgens and gonadotropins. J Clin Endocrinol Metab1977; 45: 1224. Google Scholar 20 : Effect of flutamide or cyproterone acetate on pituitary and testicular hormones in normal men. J Clin Endocrinol Metab1984; 59: 963. Google Scholar 21 : Inhibitory effects on gonadotrophin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue. Acta Endocrinol (Copenh)1979; 91: 601. Google Scholar 22 : Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med1981; 305: 663. Google Scholar 23 : Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration. J Urol1998; 160: 1685. Link, Google Scholar 24 : Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology1999; 53: 898. Google Scholar 25 : Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med1997; 337: 295. Crossref, Medline, Google Scholar 26 : Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology1995; 45: 839. Google Scholar 27 : Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. N Engl J Med1984; 311: 643. Google Scholar From the Departments of Urology and Biochemistry, and Institutes of Hormone Research and Oncology, Shaare Zedek Medical Center and Zer Laboratories, Jerusalem, Israel, National Patent Development, New Brunswick, New Jersey, and Center for Biomedical Research, Population Council, New York, New York© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited bySaad F, Fleshner N, Pickles T, Niazi T, Lukka H, Pouliot F, Martins I and Klotz L (2020) Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate CancerJournal of Urology, VOL. 204, NO. 3, (416-426), Online publication date: 1-Sep-2020.Schlegel P (2018) Efficacy and Safety of Histrelin Subdermal Implant in Patients With Advanced Prostate CancerJournal of Urology, VOL. 175, NO. 4, (1353-1358), Online publication date: 1-Apr-2006.FRIDMANS A, CHERTIN B, KOULIKOV D, LINDENBERG T, GELBER H, LEITER C, FARKAS A and SPITZ I (2018) REVERSIBILITY OF ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH PROSTATE CANCERJournal of Urology, VOL. 173, NO. 3, (784-789), Online publication date: 1-Mar-2005. Volume 163Issue 3March 2000Page: 838-844 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.Keywordscastration, maleprostateneoplasm metastasisdrug implantsprostatic neoplasmsMetricsAuthor Information BORIS CHERTIN More articles by this author IRVING M. SPITZ More articles by this author TZINA LINDENBERG More articles by this author NURIT ALGUR More articles by this author TAMI ZER More articles by this author PETR KUZMA More articles by this author ALFRED J. MOO YOUNG More articles by this author RAPHAEL CATANE More articles by this author AMICUR FARKAS More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2107370425 created "2016-06-24" @default.
• W2107370425 creator A5011864711 @default.
• W2107370425 creator A5024726200 @default.
• W2107370425 creator A5036144155 @default.
• W2107370425 creator A5045367890 @default.
• W2107370425 creator A5052064807 @default.
• W2107370425 creator A5056464485 @default.
• W2107370425 creator A5070121597 @default.
• W2107370425 creator A5075386708 @default.
• W2107370425 creator A5089063488 @default.
• W2107370425 date "2000-03-01" @default.
• W2107370425 modified "2023-10-15" @default.
• W2107370425 title "AN IMPLANT RELEASING THE GONADOTROPIN HORMONE-RELEASING HORMONE AGONIST HISTRELIN MAINTAINS MEDICAL CASTRATION FOR UP TO 30 MONTHS IN METASTATIC PROSTATE CANCER" @default.
• W2107370425 cites W1980806708 @default.
• W2107370425 cites W2013354835 @default.
• W2107370425 cites W2013649849 @default.
• W2107370425 cites W2014145760 @default.
• W2107370425 cites W2016055442 @default.
• W2107370425 cites W2016065996 @default.
• W2107370425 cites W2025053238 @default.
• W2107370425 cites W2025834323 @default.
• W2107370425 cites W2034397651 @default.
• W2107370425 cites W2042645056 @default.
• W2107370425 cites W2048766864 @default.
• W2107370425 cites W2051762621 @default.
• W2107370425 cites W2060046358 @default.
• W2107370425 cites W2079205050 @default.
• W2107370425 cites W2134349385 @default.
• W2107370425 cites W2159004290 @default.
• W2107370425 cites W2163566079 @default.
• W2107370425 cites W2169932845 @default.
• W2107370425 cites W2316095838 @default.
• W2107370425 cites W2321152237 @default.
• W2107370425 cites W2340534380 @default.
• W2107370425 cites W4293314646 @default.
• W2107370425 cites W4367362706 @default.
• W2107370425 cites W2470014550 @default.
• W2107370425 doi "https://doi.org/10.1016/s0022-5347(05)67816-0" @default.
• W2107370425 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10687989" @default.
• W2107370425 hasPublicationYear "2000" @default.
• W2107370425 type Work @default.
• W2107370425 sameAs 2107370425 @default.
• W2107370425 citedByCount "29" @default.
• W2107370425 countsByYear W21073704252012 @default.
• W2107370425 countsByYear W21073704252013 @default.
• W2107370425 countsByYear W21073704252016 @default.
• W2107370425 countsByYear W21073704252020 @default.
• W2107370425 countsByYear W21073704252021 @default.
• W2107370425 countsByYear W21073704252022 @default.
• W2107370425 countsByYear W21073704252023 @default.
• W2107370425 crossrefType "journal-article" @default.
• W2107370425 hasAuthorship W2107370425A5011864711 @default.
• W2107370425 hasAuthorship W2107370425A5024726200 @default.
• W2107370425 hasAuthorship W2107370425A5036144155 @default.
• W2107370425 hasAuthorship W2107370425A5045367890 @default.
• W2107370425 hasAuthorship W2107370425A5052064807 @default.
• W2107370425 hasAuthorship W2107370425A5056464485 @default.
• W2107370425 hasAuthorship W2107370425A5070121597 @default.
• W2107370425 hasAuthorship W2107370425A5075386708 @default.
• W2107370425 hasAuthorship W2107370425A5089063488 @default.
• W2107370425 hasConcept C121608353 @default.
• W2107370425 hasConcept C126322002 @default.
• W2107370425 hasConcept C126894567 @default.
• W2107370425 hasConcept C143998085 @default.
• W2107370425 hasConcept C170493617 @default.
• W2107370425 hasConcept C2776235491 @default.
• W2107370425 hasConcept C2776363309 @default.
• W2107370425 hasConcept C2778575703 @default.
• W2107370425 hasConcept C2778894405 @default.
• W2107370425 hasConcept C2778938600 @default.
• W2107370425 hasConcept C2779256933 @default.
• W2107370425 hasConcept C2780192828 @default.
• W2107370425 hasConcept C71315377 @default.
• W2107370425 hasConcept C71924100 @default.
• W2107370425 hasConceptScore W2107370425C121608353 @default.
• W2107370425 hasConceptScore W2107370425C126322002 @default.
• W2107370425 hasConceptScore W2107370425C126894567 @default.
• W2107370425 hasConceptScore W2107370425C143998085 @default.
• W2107370425 hasConceptScore W2107370425C170493617 @default.
• W2107370425 hasConceptScore W2107370425C2776235491 @default.
• W2107370425 hasConceptScore W2107370425C2776363309 @default.
• W2107370425 hasConceptScore W2107370425C2778575703 @default.
• W2107370425 hasConceptScore W2107370425C2778894405 @default.
• W2107370425 hasConceptScore W2107370425C2778938600 @default.
• W2107370425 hasConceptScore W2107370425C2779256933 @default.
• W2107370425 hasConceptScore W2107370425C2780192828 @default.
• W2107370425 hasConceptScore W2107370425C71315377 @default.
• W2107370425 hasConceptScore W2107370425C71924100 @default.
• W2107370425 hasIssue "3" @default.
• W2107370425 hasLocation W21073704251 @default.
• W2107370425 hasLocation W21073704252 @default.
• W2107370425 hasOpenAccess W2107370425 @default.
• W2107370425 hasPrimaryLocation W21073704251 @default.
• W2107370425 hasRelatedWork W1750535794 @default.
• W2107370425 hasRelatedWork W1979621933 @default.
• W2107370425 hasRelatedWork W1985886098 @default.
• W2107370425 hasRelatedWork W2004268698 @default.

• next